Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
← catalyst calendarNCT06647654 · readout in 43 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With iTrials S.A..
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1actual
Sites
1
Country
Argentina
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-26 | actual | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Respiratory Syncytial Virus
- Respiratory Tract Diseases
Intervention
- Biological: ABRYSVO
Primary outcome
what the primary-completion date above is the date OFRSV-associated LRTD hospitalization among infants
measured From birth through 6 months of age
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed